Xenomics enters tumor diagnostics area by licensing DNA marker for acute myeloid leukemia

By E. Janene Geiss

Philadelphia, June 7 - Xenomics, Inc. announced Wednesday that it has obtained exclusive rights to use a recently discovered genetic marker for acute myeloid leukemia for the development of new diagnostic tools.

The identification of this genetic marker will permit physicians to diagnose this type of leukemia earlier and develop more effective treatment plans, officials said in a company news release.

"Certainly the discovery of the new genetic marker will be critically important to physicians because it can provide a diagnostic tool to classify the type of [leukemia] much more rapidly than conventional techniques," David Tomei, chief executive officer and co-founder of Xenomics, said in the release.

Xenomics is a New York molecular diagnostic company that focuses on the development of DNA-based tests.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.